Medivation, Inc. (MDVN) Misses Q1 EPS by 9c, Offers Outlook

Medivation, Inc. (NASDAQ: MDVN) reported Q1 EPS of ($0.18), $0.09 worse than the analyst estimate of ($0.09). Revenue for the quarter came in at $95.7 million versus the consensus estimate of $94.64 million.

Financial Outlook

For the full year 2014, Medivation expects U.S. net sales of XTANDI to be between $540 million and $575 million. Medivation expects 2014 total operating expenses, net of cost-sharing payments from Astellas, to be between $400 million and $430 million, approximately $45 million to $50 million of which consists of non-cash stock-based compensation expense and excludes the cost of future in-licensing opportunities we may elect to pursue, if any.

For earnings history and earnings-related data on Medivation, Inc. (MDVN) click here.

You May Also Be Interested In

• Paysafe Limited (PSFE) Misses Q2 EPS by 43c; offers guidance
• SBC Medical Group Holdings Incorporated (SBC) Misses Q2 EPS by 2c
• Salem Media Group (SALM) Reports Q2 Loss of $0.11